N-methyl-N'-[3-(4-methyl-piperazin-1-yl)-phenyl]pyrimidine-4,6-diamine | 1067894-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-methyl-N'-[3-(4-methyl-piperazin-1-yl)-phenyl]pyrimidine-4,6-diamine
• CAS: 1067894-16-9
• 化学式: C₁₆H₂₂N₆
• 分子量: 298.391
• InChiKey: OGHVHYFXRAFGJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.01
• 重原子数：
  22.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.32
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-3-isocyanato-1,5-dimethoxybenzene 、 N-methyl-N'-[3-(4-methyl-piperazin-1-yl)-phenyl]pyrimidine-4,6-diamine 以 甲苯 为溶剂， 以32%的产率得到3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methyl-1-{6-[3-(4-methylpiperazin-1-yl)phenylamino]pyrimidin-4-yl}urea
  参考文献：
  名称：

  Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

  摘要：

  A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

  DOI：

  10.1021/jm2006222
• 作为产物：
  描述：

  4-氯-6-甲基氨基嘧啶 、 3-(4-甲基哌嗪-1-基)苯胺 在 溶剂黄146 作用下， 以 水 为溶剂， 反应 16.0h， 以40%的产率得到N-methyl-N'-[3-(4-methyl-piperazin-1-yl)-phenyl]pyrimidine-4,6-diamine
  参考文献：
  名称：

  Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

  摘要：

  A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

  DOI：

  10.1021/jm2006222